Nalmefene improves prognosis in patients with a large cerebral infarction: study protocol for a randomized controlled prospective trial

doi:10.3969/j.issn.2095-4344.2017.36.017

Abstract

Abstract:

BACKGROUND: Occlusion of the middle cerebral artery trunk can cause large infarctions. Clinically, thrombolytic therapy, defibrillation, vasodilation, and surgery are often used to treat these large infarctions. However, the therapeutic efficacy of these therapeutic interventions in promoting prognosis remains controversial. Nalmefene, an opioid receptor antagonist, exhibits a neuroprotective effect. Few clinical studies are reported on the therapeutic efficacy of nalmefene in the treatment of large cerebral infarctions.
OBJECTIVE: To investigate the therapeutic efficacy of nalmefene in restoring the neurologic function of patients with middle cerebral artery trunk infarction in comparison with conventional treatment as a control.
METHODS: A total of 236 patients with middle cerebral artery trunk infarction who will receive treatment at the First Hospital of Jilin University, China will be randomly divided into a control group (n=116) and a nalmefene group (n=120). Patients in the control group will receive conventional treatment. Patients in the nalmefene group will receive 10 successive days of intravenous nalmefene hydrochloride injection based on conventional treatment. The primary outcome of this study is the effective rate at 20 days (10 days after treatment). The secondary outcomes of this study include (1) the National Institutes of Health Stroke Scale (NIHSS) score at 20 days, used to evaluate neurologic function deficits; (2) Glasgow Coma Scale score at 0 (before treatment) and 10 days; (3) serum level of matrix metalloproteinase 9 at 0, 5 and 10 days (before treatment and 5 and 10 days of treatment); (4) MRI perfusion imaging of the head at 0 and 10 days. This trial was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR-IOR-17013871).
RESULTS AND CONCLUSION: Preliminary experiment results revealed that compared with the control group, NIHSS score was signficiantly decreased, effective rate was increased, Glasgow Coma Scale score was significantly increased, serum level of matrix metalloproteinase 9 was significantly decreased, cerebral blood flow and cerebral blood volume on the lesion side were signficiantly increased, and the mean transit time of contrast agent on the lesion side was significantly shortened in the nalmefene group. Findings from this study will provide clinical evidence for use of nalmefene in combination with conventional treatment for large cerebral infarctions and provide data support that this combined therapy can improve the prognosis in patients with large cerebral infarctions.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Infarction, Middle Cerebral Artery, Validation Studies, Tissue Engineering

CLC Number:

R318

Sun Jing, Li Xiao-ping, Wang Ting-ting, Hou Wei-chen. Nalmefene improves prognosis in patients with a large cerebral infarction: study protocol for a randomized controlled prospective trial[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(36): 5835-5840.

Figures/Tables 3

References

[1] Yu J, Lian Z, Wang W, et al. Parapharyngeal space acinic cell carcinoma after operation in patients with internal carotid artery embolism caused by acute large area cerebral infarction: a case report. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(6):512-514.

[2] Li T, Tian GJ, Yu JC, et al. Effects of acupuncture on nervous function in the patient of extensive cerebral infarction after operation. Zhongguo Zhen Jiu. 2008;28(12):869-872.

[3] Li XL, Xia Q, Cheng ZX, et al. Influence of beginning time of hypothermia treatment on prognosis of extensive cerebral infarction. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005; 17(3):180-182.

[4] Zheng PY, Jin Y, Zhang YE, et al. Treatment of large area acute cerebral infarction. Nao yu Shenjing Jibing Zazhi. 2001;9(3):159-160.

[5] Liao XL, Wang YL, Pan YS, et al. The Recanalization and Prognosis of Acute Cerebral Infarction Patients with Middle Cerebral Artery Occlusion after Intravenous Thrombolytic Treatment. Zhongguo Cuzhong Zazhi. 2016;11(10):824-828.

[6] Jiang W, Zhou XY, Zhou SN. Clinical Application of Vasodilators in the Acute Phase of Ischemic Stroke. Zhongguo Quanke Yixue. 2017;20(6):720-724.

[7] Yan X. Research progress of decompressive hemicraniectomy for malignant middle cerebral artery infarction. Zhonghua Shiyong Zhenduan yu Zhiliao Zazhi. 2015;29(5):435-437.

[8] Barrio P, Ortega L, Guardia J, et al. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. Clin Drug Investig. 2017;doi: 10.1007/s40261-017-0590-4.

[9] Millier A, Laramee P, Rahhali N, et al. Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model. J Stud Alcohol Drugs. 2017;78(6):867-876.

[10] Sugishita K, Su Z, Li F, et al. Gender influences [Ca(2+)](i) during metabolic inhibition in myocytes overexpressing the Na(+)-Ca(2+) exchanger. Circulation. 2001;104(17): 2101-2106.

[11] Matzke GR, Frye RF, Alexander AC, et al. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. J Clin Pharmacol. 1996;36(2):144-151.

[12] Zaki PA, Bilsky EJ, Vanderah TW, et al. Opioid receptor types and subtypes: the delta receptor as a model. Annu Rev Pharmacol Toxicol. 1996;36:379-401.

[13] Akil H, Watson SJ, Young E, et al. Endogenous opioids: biology and function. Annu Rev Neurosci. 1984;7:223-255.

[14] Chang RC, Rota C, Glover RE, et al. A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res. 2000; 854(1-2):224-229.

[15] Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016;17(4):619-626.

[16] Du R, Teng JF, Wang Y, et al. Clinical study of Butylphthalide combined with Xue Shuan Tong on serum inflammatory factors and prognosis effect of patients with cerebral infarction. Pak J Pharm Sci. 2015;28(5 Suppl):1823-1827.

[17] Gao X, Ma F, Zhao Q, et al. Acupuncture method of "Huoxue Sanfeng, Shugan Jianpi" for morning blood pressure in patients with cerebral infraction combined with essential hypertension: a randomized controlled trial. Zhongguo Zhen Jiu. 2016;36(5):459-462.

[18] Zhang C, Zhao S, Zang Y, et al. The efficacy and safety of Dl-3n-butylphthalide on progressive cerebral infarction: A randomized controlled STROBE study. Medicine (Baltimore). 2017;96(30):e7257.

[19] Fu J, Zeng M, Shen F, et al. Effects of action observation therapy on upper extremity function, daily activities and motion evoked potential in cerebral infarction patients. Medicine (Baltimore). 2017;96(42):e8080.

[20] Jia XF, Hong Z, Fan JH, et al. Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction. J Biol Regul Homeost Agents. 2016;30(3):821-826.

[21] 中华神经科学会, 中华神经外科学会. 各类脑血管疾病诊断要点[J]. 中华神经科杂志,1996;29:379-380.

[22] Siniscalchi A, Sztajzel R, Malferrari G, et al. The National Institutes of Health Stroke Scale: Its Role in Patients with Posterior Circulation Stroke. Hosp Top. 2017:1-3.

[23] Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872): 81-84.